by Barry101 | Mar 31, 2017 | Press Release
Hemispherx Biopharma Management Team Continues Its Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder ValueConference Call Scheduled for Friday, April 7th at 11:00 AM EDTPHILADELPHIA, March 31,...
by Barry101 | Mar 6, 2017 | Press Release
PHILADELPHIA, March 06, 2017 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it has met a major milestone, the commencement of sales of recently manufactured Ampligen in international...
by Barry101 | Feb 2, 2017 | Press Release
PHILADELPHIA, Feb. 02, 2017 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced today that it has entered into definitive agreements with several institutional investors for an offering of shares of...
by Barry101 | Feb 1, 2017 | Press Release
The attached letter can also be found on the company's website at http://ir.hemispherx.net/Events_Presentations
by Barry101 | Jan 26, 2017 | Press Release
PHILADELPHIA, Jan. 26, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) announced today that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access Program (EAP) in Europe has been shipped with receipt confirmed on January 26....
by Barry101 | Jan 11, 2017 | Press Release
First patient treated in the NetherlandsPHILADELPHIA, Jan. 11, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that the rintatolimod European early access program (EAP) designed to enable access...
